Melting pot

Houston named a top city for minority entrepreneur success

The Bayou City has been named the top Texas metro for minority entrepreneurial success. Photo by Zview/Getty Images

Houston reigns as the top major metro area in Texas for successful minority entrepreneurs, a new study shows.

The Houston area ranks No. 11 in the study, done by lending marketplace LendingTree, with Dallas-Fort Worth at No. 17, Austin at No. 29, and San Antonio at No. 34. In all, the study measures the success of minority entrepreneurs in the country's 50 largest metro areas.

Houston is no stranger to high marks for its minority-entrepreneur environment.

In 2017, Expert Market ranked Houston the No. 1 city in the U.S. for minority entrepreneurs. A year earlier, Rice University's Kinder Institute noted that the Houston area ranked sixth in the U.S. for metro-area concentrations of minority entrepreneurs.

For its ranking, LendingTree looked at four metrics:

  • Percentage of self-employed minorities in each metro area. (It's 2.5 percent in Houston).
  • Minority businesses ownership parity. A metro area scores well in this regard if the share of minority-owned businesses aligns with the percentage of minority residents. (Houston received a score of 59 in this category, with 100 being a perfect score.)
  • Percentage of minority-owned businesses that posted at least $500,000 in annual revenue. (It's 46.7 percent in Houston.)
  • Percentage of minority-owned businesses that have operated for at least six years. (It's 56.2 percent in Houston).

Ingrid Robinson, president of the Houston Minority Supplier Development Council, credits the Houston area's strong showing in the LendingTree study to a number of factors.

For one thing, minority entrepreneurs in Houston enjoy access to a vast array of resources at each stage of a business' growth, she says. For example, Houston Minority Supplier Development Council tailors its programs, seminars, and services to minority businesses in four revenue categories, ranging from less than $1 million a year to more than $50 million a year.

Furthermore, Robinson says, business development groups in the Houston area work more collaboratively than they do in many other regions.

"We truly try not to duplicate efforts, but to support one another and direct minority entrepreneurs to the appropriate organization that can best meet their needs," she says.

Robinson underscores the diversity of industries in the Houston area, including energy, healthcare, and aerospace. This diversity helps sustain business activity during tough economic times, she says.

Then, there's the fact that Houston is diverse in its demographics. A report released by Rice University proclaimed Houston is the most racially and ethnically diverse major metro area in the U.S. More than 145 languages are spoken throughout the region by a robust mix of white, Hispanic, African-American, and Asian residents.

"Houston is the only place in America that you can go to today that reflects the demographics projected for our entire country in 20 years," Robinson says. "So we have the opportunity to lead the way in showing the rest of our nation that minority business is good business for everyone."

Minority-owned businesses in the Houston area enjoy strong support from local, county, and state elected officials, Robinson says.

"The tone set by our governing bodies to ensure the broadest inclusion of minority entrepreneurs in governmental contracts makes Houston attractive to individuals seeking opportunities," Robinson says.

During his 2015 election campaign, Houston Mayor Sylvester Turner stressed that a competitive business environment — including a thriving community of minority-owned, woman-owned and small businesses — "is critical to Houston's future economic health."

Houston-based Moleculin has three different oncology technologies currently in trials. Getty Images

Immunotherapy and personalized medicine get all the headlines lately, but in the fight against cancer, a natural compound created by bees could beat them in winning one battle.

In 2007, chairman and CEO Walter Klemp founded Moleculin Biotech Inc. as a private company. The former CPA had found success in life sciences with a company that sold devices for the treatment of acne. That introduction into the field of medical technology pushed him toward more profound issues than spotty skin.

"Coincidentally, the inventor of that technology had a brother who was a neuro-oncologist at MD Anderson," Klemp recalls.

The since-deceased Dr. Charles Conrad slowly lured Klemp into what he calls the "cancer ecosphere" of MD Anderson. In 2016, the company went public. And it looks like sooner rather than later, it could make major inroads against some of the toughest cancers to beat.

Klemp observed that while Houston has the world's largest medical center, "the tragic irony" is that other cities have far more biotech money ready to be invested.

"The Third Coast is really starved for capital," he says. "What drew me into this was I was one of the few entrepreneurs that lived here that knew the ropes in terms of tapping into East and West Coast capital structures and could make that connection for them."

The company has three core technologies currently being tested with some success, but the most promising is called WP1066, named for researcher Waldemar Priebe, "a rock star" in his native Poland, according to Klemp, who works at MD Anderson. Though Priebe came to the U.S. in the 1980s, he is still an adjunct professor at the University of Warsaw and conducts some of his trials in Poland because it's easier to get grant money there.

WP1066 uses propolis, a compound of beeswax, sap and saliva that bees produce to seal small areas of their hives, as a base. The molecular compound that Priebe discovered affects STAT3 (signal transducer and activator of transcription), a transcription factor that encourages tumor development. In short, the active compound in WP1066 both downregulates the STAT3, a long-time Holy Grail in the cancer research world, and directly attacking the tumor, but also quieting T Cells, which allows the body's own immune system to fight the cancer itself. Essentially, it works both as chemotherapy and immunotherapy.

WP1066 is demonstrating drug-like properties in trials at MD Anderson on glioblastoma, the aggressive brain cancer that recently took the life of the hospital's former president, John Mendelsohn, as well as John McCain and Beau Biden. It is also being tested against pancreatic cancer, one of the most virulent killers cancer doctors combat.

Priebe also created Annamycin, named for his oldest daughter, a first-line chemotherapy drug that fights Acute Myeloid Leukemia without the cardiotoxicity that can damage patients' hearts even as they beat their cancer.

WP1122 uses yet another mechanism to fight cancer.

"Most people don't know that morphine is essentially a modified version of heroin," Klemp explains.

The difference between the poppy-based drugs? Heroin can cross the blood-brain barrier. It's described as the dicetyl ester of morphine. WP1122 is the dicetyl ester of 2DG (2-Deoxyglucose), a glycolysis inhibitor, which works by overfilling tumor cells with fake glucose so that they can't consume the real glucose that makes them grow.

"The theory is, we could feed you so full of junk food that eventually you'd starve to death," Klemp elucidates. It can cross the blood-brain barrier and is metabolized slowly, meaning that it can be made into a drug in a way that 2DG cannot.

What's impressive about Moleculin is its diversity of drugs. Most companies have one drug that gets all or most of the attention. Moleculin has strong hopes for all three currently in trials.

"It's essentially multiple shots on the goal," says executive vice president and CFO Jonathan Foster.

Moleculin has 13 total employees, five of whom are based in Houston. An office in the Memorial Park area serves as a landing pad for employees and collaborators from around the world to get their work done when in Space City. The virtual office set-up works for the company because experts can stay in their home cities to get their work done. And that work is on its way to saving scores of lives.